10/28/2026 | Press release | Distributed by Public on 10/28/2026 10:45
Excerpt
As biology shifts toward an engineering discipline, a Los Angeles biotech company, eXoZymes (Nasdaq: EXOZ), is betting that engineered enzyme systems can bridge the gap between digital molecule design and physical production.